Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
BUSINESS
Mitsubishi Chemical Scraps Muse Cell Therapy Program
Mitsubishi Chemical Group said on February 14 that it will terminate the development of its multi-lineage differentiating stress enduring (Muse) cell therapy CL2020, which has been clinically tested across seven diseases in Japan, including investigator-led trials. The decision was made…
To read the full story
Related Article
- Mitsubishi Chemical Scraps Regenerative Medicine Unit
February 28, 2024
- Mitsubishi Sent Letter Agreeing to Call Off Muse Cell License Deal: Researchers
April 24, 2023
- Mitsubishi Chemical to Fix “Overextension” of Pharma Biz, Focus on 4 Therapeutic Areas, Japan/US: CEO
February 28, 2023
- Investigators Doubt Mitsubishi’s Trial Data on Muse Cell Therapy; Program Aborted without Notice
February 17, 2023
BUSINESS
- Santen Files RVL Pharma’s Droopy Eyelid Drug in Japan
December 27, 2024
- J&J Bags Kaken’s STAT6 Inhibitor, Set to Take 6% Stake in Japan Firm
December 27, 2024
- Meiji Pharma Sues CDP Lawmaker for Defamation over Kostaive
December 26, 2024
- ASKA In-Licenses Another Women’s Health Drug from Insud
December 26, 2024
- Sandoz’s Rituximab Biosimilar Adds Pediatric ITP Indication
December 26, 2024
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel on November 28 agreed on a plan to legally require pharma companies to set up…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…